查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1519835

2024-2032 年按治疗、癌症类型（非小细胞肺癌、小细胞肺癌）、配销通路和地区分類的肺癌治疗市场报告

Lung Cancer Therapeutics Market Report by Therapy, Cancer Type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer ), Distribution Channel, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 137 Pages | 商品交期: 2-3个工作天内

价格

IMARC Group年，全球肺癌治疗市场规模达301.888亿美元。由于世界各地吸烟和环境污染加剧了肺癌发病率的迅速上升、个体化治疗（包括基于基因图谱的治疗）的进一步发展以及技术的不断进步，市场正在经历稳定增长。发现病理。

肺癌治疗市场分析：

主要市场驱动因素：全球范围内与肺癌相关的大量盛行率和死亡率正在创造较高的肺癌治疗市场需求。

主要市场趋势：随着越来越多针对肿瘤细胞特定基因突变的疗法的出现，市场将朝着个人化医疗的方向发展。此外，将人工智慧和机器学习纳入诊断过程可提高获得此类治疗的机会和精确度，这也是肺癌治疗市场的主要趋势之一。

地理趋势：市场分析表明，由于强大的医疗保健结构、医疗支出和先进肿瘤治疗的早期使用，北美在肺癌治疗方面处于领先地位。包括中国和印度在内的亚太地区正在凭藉快速增长的医疗保健意识和改进的医疗保健服务系统来推动市场发展。

竞争格局：根据肺癌治疗市场概况，基于成熟的製药巨头和新兴生物公司的存在，市场竞争非常激烈。此外，各大公司正在透过研发和合作伙伴关係来创新和扩展其产品线。

挑战与机会：新癌症药物的高成本成为低收入和中等收入经济体肺癌治疗方法的主要挑战，造成了可近性差距。然而，随着肺癌治疗市场最近开发具有成本效益的仿製药和生物相似药的机会，这些挑战变得更加严峻。

肺癌治疗市场趋势：

全球肺癌发生率上升

促进肺癌治疗市场成长的另一个因素是肺癌发生率的增加。美国癌症协会对美国肺癌的估计，到2024年，新发癌症人数约为234,580人，其中男性116,310人，女性118,270人。死亡人数将达125,070人，其中男性死亡65,790人，女性死亡59,280人。全球人口的指数级增长以及吸烟、空气和环境污染以及有害工作场所事件等导致肺癌的有害因素的普遍存在都支持了这一点。因此，这也影响着肺癌治疗市场的统计数据。由于肺癌发生率不断增加，需要采取更积极的措施。因此，用于肺癌治疗的方法（包括药物）的开发和改进正在不断发展。供应的增加为製药公司进行测试、开发新产品和扩大品种提供了更多理由。因此，对更有效药物的需求正在增长。因此，肺癌治疗是成长最快的。

个人化医疗的创新

随着个人化医疗的发展，肺癌治疗市场的成长正在显着成长，个人化医疗根据遗传特征对每位患者进行治疗。近年来，製药业开发并生产了精确攻击此类突变的药物。事实证明，这些药物比化疗更有效，副作用也更少。肺癌治疗市场预测表明，个人化医疗将成为该肿瘤治疗的基础；这意味着治疗效率会提高，因为处方会更准确。此外，诊断技术的进步以及对影响肺癌进展的遗传因素的深入了解推动了对精准医学的日益重视。因此，製药业对个人化解决方案的投资不断扩大，使药物开发与特定患者的需求保持一致，并大大推动肺癌治疗市场的发展。

诊断和治疗的不断进步

技术创新推动市场，特别是在诊断和治疗方面。此外，改进的影像和人工智慧辅助诊断工具可以更早、更准确地检测肺癌。除此之外，这个概念也改变了治疗效果和患者復原的游戏规则。除此之外，肺癌治疗市场的最新发展包括引入新的和正在开发的微创手术技术、增强的放射治疗方法和先进的药物传输系统，包括基于奈米颗粒的化疗製剂。此外，先进技术的准确性和有效性无法想像舒适的治疗和可恢復的患者视野。此外，所有这些技术的结合正在创造积极的市场前景。

肺癌治疗市场细分：

IMARC Group提供了每个细分市场的主要趋势分析，以及 2024-2032 年全球、区域和国家层面的预测。我们的报告根据治疗、癌症类型和配销通路对市场进行了分类。

治疗分手：

标靶治疗

贝伐珠单抗

达拉非尼/曲美替尼

盐酸厄洛替尼

奥西替尼

其他的

免疫疗法

杜瓦鲁单抗

纳武单抗

阿替珠单抗

帕博利珠单抗

放射治疗

外樑

内樑

系统性

化疗

标靶治疗占据大部分市场份额

该报告根据该疗法对市场进行了详细的细分和分析。这包括标靶治疗（贝伐珠单抗、达拉非尼/曲美替尼、盐酸厄洛替尼、奥西替尼等）；免疫疗法（durvalumab、nivolumab、atezolizumab 和 pembrolizumab）；放射治疗（体外、内照射和全身放射治疗）；和化疗。根据该报告，标靶治疗占最大部分。

该疗法是最大的，因为与传统化疗相比，它更有效且副作用更少。它包括能够准确识别和杀死癌细胞的药物或其他材料。这种治疗可能针对区分癌细胞与其他细胞的分子和遗传特征。此外，目前对肺癌遗传的了解程度允许识别许多特定的分子靶点，以及相应地可以阻止这些标靶活化的药物。根据肺癌治疗市场预测，分子生物学和遗传学的发展将不断增加可用于对抗所述疾病的标靶和药物的数量。因此，有理由认为，由于新的潜在标靶和药物的出现，标靶治疗领域将继续发展。

按癌症类型划分：

非小细胞肺癌 (NSCLC)

小细胞肺癌 (SCLC)

非小细胞肺癌（NSCLC）占据业界最大份额

报告还根据癌症类型提供了详细的市场细分和分析。这包括非小细胞肺癌（NSCLC）和小细胞肺癌（SCLC）。报告显示，非小细胞肺癌（NSCLC）占据最大的肺癌治疗市场。

非小细胞肺癌由于其高盛行率而在市场上占据最大份额。就个体而言，这些亚型具有共同的病理变异，但它们的进展速度比小细胞肺癌慢。因此，全球非小细胞肺癌的高盛行率对不同亚型的肺癌治疗市场产生了巨大的需求，从而激励製药公司和研究人员专注于开发能够有效治疗亚型基因和分子差异的疗法和免疫疗法。此外，NSCLC分子发病机制不断变化的能力也保证了精准医疗的发展使得NSCLC与市场具有相关性。

按配销通路划分：

医院药房

零售药局

网路药局

其他

医院药房代表领先的细分市场

该报告根据配销通路对市场进行了详细的细分和分析。这包括医院药房、零售药房、线上药房等。报告称，医院药局是最大的细分市场。

由于肺癌治疗方法的复杂性和先进性，医院药局是肺癌治疗领域最大的通路。医生需要在受控环境下进行治疗，包括化疗方案，需要仔细调节以避免副作用。根据肺癌治疗市场分析，大多数肺癌治疗都是针对住院患者，因为需要化疗、标靶治疗和免疫治疗等复杂治疗根据肺癌治疗市场分析，大多数肺癌治疗都是针对住院患者，因为需要化疗、靶向治疗和免疫疗法用于化疗、标靶治疗和免疫疗法等复杂疗法。此外，医院药局对于促进肺癌综合护理至关重要，因为患者可以立即从同一家可以协调肿瘤科、外科和放射科的医院获得所有所需的治疗。除此之外，中心性的集中确保患者以最小的延迟接受治疗，从而提高治疗的有效性。此外，对基础设施和人员专业知识的需求正在增加肺癌治疗市场的收入。

按地区划分：

北美洲

美国

加拿大

亚太

中国

日本

印度

韩国

澳洲

印尼

其他的

欧洲

德国

法国

英国

义大利

西班牙

俄罗斯

其他的

拉丁美洲

巴西

墨西哥

其他的

中东和非洲

北美市场领先，占据最大的肺癌治疗市场份额

该报告还对所有主要区域市场进行了全面分析，其中包括北美（美国和加拿大）；亚太地区（中国、日本、印度、韩国、澳洲、印尼等）；欧洲（德国、法国、英国、义大利、西班牙、俄罗斯等）；拉丁美洲（巴西、墨西哥等）；以及中东和非洲。报告称，北美是肺癌治疗的最大区域市场。

由于疾病盛行率高、医疗基础设施先进以及医疗支出最高的因素之一，北美拥有最大的区域肺癌治疗市场份额。除此之外，美国和欧元区国家在研发方面的高额政府贡献和私营部门支持也在北美市场的成长中发挥关键作用。此外，加速投资开发诊断和治疗肺癌的技术和措施正在积极影响肺癌治疗市场的收入。正如肺癌治疗市场成长趋势所示，在过去十年中，各种标靶疗法和免疫疗法已被开发并用于肺癌的治疗。此外，整个地区的监管环境也有对癌症药物快速通道的友善政策。此外，整个地区患者的高水准意识和保险覆盖范围确保北美继续主导全球市场。

本报告回答的关键问题：

  • 迄今为止，全球肺癌治疗市场表现如何，未来几年将如何表现？
  • 全球肺癌治疗市场的驱动因素、限制因素和机会是什么？
  • 每个驱动因素、限制因素和机会对全球肺癌治疗市场有何影响？
  • 主要区域市场有哪些？
  • 哪些国家代表了最具吸引力的肺癌治疗市场？
  • 基于该疗法的市场区隔是什么？
  • 肺癌治疗市面上哪种疗法最具吸引力？
  • 根据癌症类型分類的市场是怎么样的？
  • 肺癌治疗市场中哪种癌症类型最具吸引力？
  • 基于配销通路的市场区隔是什么？
  • 肺癌治疗市场中最具吸引力的配销通路是什么？
  • 市场竞争结构如何？
  • 谁是全球肺癌治疗市场的主要参与者/公司？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球肺癌治疗市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：透过疗法

  • 标靶治疗
    • 市场走向
    • 关键环节
      • 贝伐珠单抗
      • 达拉非尼/曲美替尼
      • 盐酸厄洛替尼
      • 奥西替尼
      • 其他的
    • 市场预测
  • 免疫疗法
    • 市场走向
    • 关键环节
      • 杜瓦鲁单抗
      • 纳武单抗
      • 阿替珠单抗
      • 帕博利珠单抗
    • 市场预测
  • 放射治疗
    • 市场走向
    • 关键环节
      • 外樑
      • 内樑
      • 系统性
    • 市场预测
  • 化疗
    • 市场走向
    • 市场预测

第 7 章：市场区隔：按癌症类型

  • 非小细胞肺癌（NSCLC）
    • 市场走向
    • 市场预测
  • 小细胞肺癌 (SCLC)
    • 市场走向
    • 市场预测

第 8 章：市场区隔：按配销通路

  • 医院药房
    • 市场走向
    • 市场预测
  • 零售药局
    • 市场走向
    • 市场预测
  • 网路药局
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 9 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场走向
    • 市场细分：按国家/地区
    • 市场预测

第 10 章：驱动因素、限制与机会

  • 概述
  • 司机
  • 限制
  • 机会

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 13 章：价格分析

第14章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • AbbVie Inc.
    • Amgen Inc.
    • AstraZeneca Plc
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb Company
    • Daiichi Sankyo Company Limited
    • Eli Lilly and Company
    • GSK PLC
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Roche Holding AG
    • Takeda Pharmaceutical Company Limited
Product Code: SR112024A8336

The global lung cancer therapeutics market size reached US$ 30,188.8 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 70,084.5 Million by 2032, exhibiting a growth rate (CAGR) of 9.52% during 2024-2032. The market is experiencing steady growth driven by the rapid increase in the incidence of lung cancer, which is aggravated by smoking and environmental pollution around the world, the further development of individualized treatment, including based on the gene profile, and the continuous advancement of technology for diagnosing the disease, to ensure early detection of the pathology.

Lung Cancer Therapeutics Market Analysis:

Major Market Drivers: The massive prevalence and mortality associated with lung cancer worldwide is creating a high lung cancer therapeutics market demand.

Key Market Trends: The market will develop in the direction of personalized medicine as an increasing number of therapies addressing particular genetic mutations in tumor cells are created. Additionally, the incorporation of AI and machine learning in the diagnostic processes enhancing the chances and precision of accessing such treatments is acting as one of the major lung cancer therapeutics market trends.

Geographical Trends: The market analysis states that North America leads the market regarding lung cancer therapeutics due to the robust healthcare structures, health expenditures, and early use of advanced oncology treatments. Asia Pacific region, including China and India, is driving the market based on rapidly growing healthcare awareness and improved healthcare delivery systems.

Competitive Landscape: According to the lung cancer therapeutics market overview, the market is highly competitive based on the existence of well-established pharmaceutical giants and new emerging biofirms. Additionally, major companies are innovating and expanding their product lines through research and development and partnerships.

Challenges and Opportunities: The high cost of new cancer medicines emerges as the main challenge to the lung cancer therapeutics revelations to the low- and middle-income economies, creating accessibility gaps. However, such challenges amplify as lung cancer therapeutics market recent opportunities for developing cost-effective generics and biosimilars.

Lung Cancer Therapeutics Market Trends:

Rising incidence of lung cancer worldwide

Another factor contributing to the lung cancer therapeutics market growth is the increasing incidence of lung cancer. The American Cancer Society made an estimation of lung cancer in the US by 2024. The number of new cancer occurrences should approximately equal 234,580 individuals, including 116,310 males and 118,270 females. The number of deaths will equal 125,070 deaths, which involves 65,790 male deaths and 59,280 female deaths. This can be supported by the exponentially growing global population and the prevalence of harmful factors causing lung cancer such as smoking, air and environmental pollution, and harmful workplace events. Thus, this is also influencing the lung cancer therapeutics market statistics. Due to the constantly increasing incidence of lung cancer, more active measures are needed. Accordingly, the development and improvement of methods, including drugs, for lung cancer treatment are constantly developing. Increased supply creates more reason for pharmaceutical companies to conduct tests and develop new ones and expand their assortment. Accordingly, demand for more effective drugs is growing. Thus, lung cancer therapeutics is the fastest-growing.

Innovations in personalized medicine

The lung cancer therapeutics market growth is increasing significantly with the development of personalized medicine, which treats each patient based on genetic features. In recent years, the drug industry has developed and produced drugs that precisely attack such mutations. These have proven to be more effective than chemotherapy, causing fewer side effects. The lung cancer therapeutics market forecast suggests that personalized medicine will become the basis of therapy for this oncology; this means an increase in the efficiency of therapy since the prescription will be more accurate. Furthermore, the growing emphasis on precision medicine is fueled by technological progress in diagnostics and an increased understanding of genetic factors influencing lung cancer progression. Consequently, the pharmaceutical industry's investment in personalized solutions continues to expand, aligning drug development with specific patient needs and substantially driving the lung cancer therapeutics market forward.

Continuous advancements in diagnostics and treatment

Technological innovations drive the market, particularly in diagnostics and treatment delivery. In addition, improved imaging and AI-assisted diagnostic tools allow lung cancer detection early and more accurately. Along with this, this notion is a game-changer for treatment efficacy and patient recovery. Apart from this, the lung cancer therapeutics market recent developments include the introduction of new and developing minimally invasive surgery techniques, enhanced radiation treatment approaches, and advanced drug-delivery systems, including nanoparticle-based chemo preparations. In addition, the accuracy and effectiveness of advanced technology cannot imagine a comfortable treatment and recoverable patient view. Furthermore, the combination of all these technologies is creating a positive market outlook.

Lung Cancer Therapeutics Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on therapy, cancer type, and distribution channel.

Breakup by Therapy:

Targeted Therapy

Bevacizumab

Dabrafenib/Trametinib

Erlotinib Hydrochloride

Osimertinib

Others

Immunotherapy

Durvalumab

Nivolumab

Atezolizumab

Pembrolizumab

Radiation Therapy

External Beam

Internal Beam

Systemic

Chemotherapy

Targeted therapy accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the therapy. This includes targeted therapy (bevacizumab, dabrafenib/trametinib, erlotinib hydrochloride, Osimertinib and others); immunotherapy (durvalumab, nivolumab, atezolizumab and pembrolizumab); radiation therapy (external beam, internal beam and systemic); and chemotherapy. According to the report, targeted therapy represented the largest segment.

The therapy segment is the largest as it is more efficient and has fewer side effects compared to traditional chemotherapy. It includes drugs or other materials that can accurately recognize and kill cancer cells. This treatment is probably directed at the molecular and genetic features that differentiate cancer cells from others. In addition, the current level of understanding of genetic aspects of lung cancer allows the identification of many specific molecular targets and, correspondingly, agents that can prevent the activation of these targets. According to the lung cancer therapeutics market forecast, the development of molecular biology and genetics will consistently increase the number of targets and agents that could be used to combat the described disease. Hence, it is reasonable to suppose that the targeted therapy segment will continue developing due to the appearance of new potential targets and agents.

Breakup by Cancer Type:

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Non-Small Cell Lung Cancer (NSCLC) holds the largest share of the industry

A detailed breakup and analysis of the market based on the cancer type have also been provided in the report. This includes non-small cell lung cancer (NSCLC), and small cell lung cancer (SCLC). According to the report, non-small cell lung cancer (NSCLC) accounted for the largest lung cancer therapeutics market share.

The non-small cell lung cancer segment holds the largest share in the market due to its high prevalence. Individually, the subtypes share pathological variations, but they progress more slowly than small-cell lung cancer. As such, the high global prevalence of NSCLC creates a sizable lung cancer therapeutics market demand for the different subtypes, thereby incentivizing pharmaceutical companies and researchers to focus on developing therapies and immunotherapies that can treat the subtype gene and molecular distinctions effectively. In addition, the changing molecular pathogenesis capacity for NSCLC also ensures that the development of precision medicine causes NSCLC to have a correlation with the market.

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Other

Hospital pharmacies represents the leading market segment

The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes hospital pharmacies, retail pharmacies, online pharmacies, and others. According to the report, hospital pharmacies represented the largest segment.

Hospital pharmacies are the largest channel of distribution in the lung cancer therapeutics segment due to the complicated and advanced nature of the therapies for the disease. Doctors require a controlled environment to administer treatments, including chemotherapy solutions, which need to be carefully regulated to avoid side effects. According to the lung cancer therapeutics market analysis, most lung cancer therapies are for inpatients given the need for complex therapies such as chemotherapy, targeted therapy, and immunotherapies According to the lung cancer therapeutics market analysis, most lung cancer therapies are for inpatients given the need for complex therapies such as chemotherapy, targeted therapy, and immunotherapies. Additionally, hospital pharmacies are critical in facilitating integrated lung cancer care as the patient can access all the required treatments immediately and from the same hospital that can coordinate oncology, surgery, and radiology departments. Apart from this, the centralization of centrality ensures the patient undergoes therapy with minimal delays which improves the effectiveness of the therapeutics. Furthermore, the demand for infrastructure and personnel expertise is increasing the lung cancer therapeutics market revenue.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest lung cancer therapeutics market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for lung cancer therapeutics.

North America has the largest regional lung cancer therapeutics market share due to high disease prevalence, advanced healthcare infrastructure, and one of the highest healthcare spender factors. Along with this, high government contribution and private sector support in the US and Eurozone countries, spent on research and development, also play a key role in the growth of the North American market. Furthermore, the accelerating investments to develop technologies and initiatives to diagnose and treat lung cancer are influencing lung cancer therapeutics market revenue positively. As the lung cancer therapeutics market growth trend shows, in the past decade, various targeted therapies and immunotherapies have been developed and used in the treatment of lung cancer. Furthermore, the regulatory environment across the region also has a friendly policy of fast-track cancer drugs. Moreover, the high levels of patient awareness across the region, and insurance coverage ensures North America continues to dictate the global market.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the lung cancer therapeutics industry include:

AbbVie Inc.

Amgen Inc.

AstraZeneca Plc

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb Company

Daiichi Sankyo Company Limited

Eli Lilly and Company

GSK PLC

Merck & Co. Inc.

Novartis AG

Pfizer Inc.

Roche Holding AG

Takeda Pharmaceutical Company Limited

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

The major lung cancer therapeutics market companies swiftly develop their product portfolios. As R&D remains critically important in their aim to expand, these companies, Roche, Pfizer, AstraZeneca, and other influential giants, are recognized as the most innovative pharmaceutical firms globally. In particular, they are developing targeted therapy and immunotherapy, which showed encouraging outcomes in addressing numerous lung cancer subtypes. Therefore, this is acting as one of the major market trends. In addition, the companies invest in advanced clinical trials to develop new indication opportunities, significantly expanding the imaginable market for their products. Furthermore, the M&A activity is also very high in the industry where several companies attempt to purchase all competitors and utilize all the latest technology available on the market. Thus, the need to stay competitive in the market for therapeutic results and improved patient outcomes.

Lung Cancer Therapeutics Market News:

March 26, 2024: AbbVie Inc. entered into a definitive agreement to acquire clinical-stage biopharmaceutical company Landos Biopharma for $212.5 million. The optimal acquisition strengthens AbbVie's pipeline in its target therapeutic area of inflammatory and autoimmune diseases.

March 19, 2024: AstraZeneca Plc acquired oncology biotech Fusion Pharmaceuticals for $2.4bn, acquiring expertise in a developing field of a less toxic and more targeted form of radiotherapy to catch up with the Swiss Novartis.

Key Questions Answered in This Report:

  • How has the global lung cancer therapeutics market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global lung cancer therapeutics market?
  • What is the impact of each driver, restraint, and opportunity on the global lung cancer therapeutics market?
  • What are the key regional markets?
  • Which countries represent the most attractive lung cancer therapeutics market?
  • What is the breakup of the market based on the therapy?
  • Which is the most attractive therapy in the lung cancer therapeutics market?
  • What is the breakup of the market based on the cancer type?
  • Which is the most attractive cancer type in the lung cancer therapeutics market?
  • What is the breakup of the market based on the distribution channel?
  • Which is the most attractive distribution channel in the lung cancer therapeutics market?
  • What is the competitive structure of the market?
  • Who are the key players/companies in the global lung cancer therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Lung Cancer Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Therapy

  • 6.1 Targeted Therapy
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Bevacizumab
      • 6.1.2.2 Dabrafenib/Trametinib
      • 6.1.2.3 Erlotinib Hydrochloride
      • 6.1.2.4 Osimertinib
      • 6.1.2.4 Others
    • 6.1.2 Market Forecast
  • 6.2 Immunotherapy
    • 6.2.1 Market Trends
    • 6.2.2 Key Segments
      • 6.2.2.1 Durvalumab
      • 6.2.2.2 Nivolumab
      • 6.2.2.3 Atezolizumab
      • 6.2.2.4 Pembrolizumab
    • 6.2.2 Market Forecast
  • 6.3 Radiation Therapy
    • 6.3.1 Market Trends
    • 6.3.2 Key Segment
      • 6.3.2.1 External Beam
      • 6.3.2.2 Internal Beam
      • 6.3.2.3 Systemic
    • 6.3.2 Market Forecast
  • 6.4 Chemotherapy
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Cancer Type

  • 7.1 Non-small Cell Lung Cancer (NSCLC)
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Small Cell Lung Cancer (SCLC)
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Retail Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Pharmacies
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AbbVie Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Amgen Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 AstraZeneca Plc
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Boehringer Ingelheim International GmbH
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Bristol-Myers Squibb Company
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Daiichi Sankyo Company Limited
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 Eli Lilly and Company
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 GSK PLC
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Merck & Co. Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 Novartis AG
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
    • 14.3.11 Pfizer Inc.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
    • 14.3.12 Roche Holding AG
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
    • 14.3.13 Takeda Pharmaceutical Company Limited
      • 14.3.13.1 Company Overview
      • 14.3.13.2 Product Portfolio

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

List of Figures

  • Figure 1: Global: Lung Cancer Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018-2023
  • Figure 3: Global: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 4: Global: Lung Cancer Therapeutics Market: Breakup by Therapy (in %), 2023
  • Figure 5: Global: Lung Cancer Therapeutics Market: Breakup by Cancer Type (in %), 2023
  • Figure 6: Global: Lung Cancer Therapeutics Market: Breakup by Distribution Channel (in %), 2023
  • Figure 7: Global: Lung Cancer Therapeutics Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Lung Cancer Therapeutics (Targeted Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Lung Cancer Therapeutics (Targeted Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Lung Cancer Therapeutics (Immunotherapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Lung Cancer Therapeutics (Immunotherapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Lung Cancer Therapeutics (Radiation Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Lung Cancer Therapeutics (Radiation Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Lung Cancer Therapeutics (Chemotherapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Lung Cancer Therapeutics (Chemotherapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Lung Cancer Therapeutics (Non-small Cell Lung Cancer (NSCLC)) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Lung Cancer Therapeutics (Non-small Cell Lung Cancer (NSCLC)) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Lung Cancer Therapeutics (Small Cell Lung Cancer (SCLC)) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Lung Cancer Therapeutics (Small Cell Lung Cancer (SCLC)) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Lung Cancer Therapeutics (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Lung Cancer Therapeutics (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Lung Cancer Therapeutics (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Lung Cancer Therapeutics (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Lung Cancer Therapeutics (Online Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Lung Cancer Therapeutics (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Lung Cancer Therapeutics (Other Distribution Channels) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Lung Cancer Therapeutics (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: North America: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: North America: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: United States: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: United States: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Canada: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Canada: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Asia-Pacific: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Asia-Pacific: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: China: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: China: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Japan: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Japan: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: India: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: India: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: South Korea: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: South Korea: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Australia: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Australia: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Indonesia: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Indonesia: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Others: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Others: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Europe: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Europe: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Germany: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Germany: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: France: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: France: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: United Kingdom: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: United Kingdom: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Italy: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Italy: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Spain: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Spain: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Russia: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Russia: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Others: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Others: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Latin America: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Latin America: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Brazil: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Brazil: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Mexico: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Mexico: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Others: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Others: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Middle East and Africa: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Middle East and Africa: Lung Cancer Therapeutics Market: Breakup by Country (in %), 2023
  • Figure 76: Middle East and Africa: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Global: Lung Cancer Therapeutics Industry: Drivers, Restraints, and Opportunities
  • Figure 78: Global: Lung Cancer Therapeutics Industry: Value Chain Analysis
  • Figure 79: Global: Lung Cancer Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Lung Cancer Therapeutics Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Lung Cancer Therapeutics Market Forecast: Breakup by Therapy (in Million US$), 2024-2032
  • Table 3: Global: Lung Cancer Therapeutics Market Forecast: Breakup by Cancer Type (in Million US$), 2024-2032
  • Table 4: Global: Lung Cancer Therapeutics Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 5: Global: Lung Cancer Therapeutics Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Lung Cancer Therapeutics Market: Competitive Structure
  • Table 7: Global: Lung Cancer Therapeutics Market: Key Players